Northern Trust Corp Acquires 40,134 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Northern Trust Corp increased its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL) by 7.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 589,635 shares of the company’s stock after purchasing an additional 40,134 shares during the quarter. Northern Trust Corp owned 0.86% of Replimune Group worth $7,140,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Sterling Capital Management LLC boosted its holdings in shares of Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock valued at $26,000 after buying an additional 1,655 shares during the period. Tower Research Capital LLC TRC boosted its stake in Replimune Group by 696.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock worth $82,000 after purchasing an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd raised its position in Replimune Group by 8,798.9% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after buying an additional 8,183 shares during the last quarter. XTX Topco Ltd bought a new stake in Replimune Group in the 4th quarter valued at approximately $137,000. Finally, Sei Investments Co. bought a new stake in Replimune Group in the 4th quarter valued at approximately $148,000. 92.53% of the stock is owned by institutional investors.

Replimune Group Trading Up 4.5%

Shares of NASDAQ:REPL opened at $8.20 on Tuesday. Replimune Group, Inc. has a 1 year low of $4.92 and a 1 year high of $17.00. The business’s 50 day simple moving average is $8.87 and its 200 day simple moving average is $11.30. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The company has a market capitalization of $631.52 million, a P/E ratio of -2.67 and a beta of 0.68.

Analysts Set New Price Targets

REPL has been the subject of a number of recent research reports. JPMorgan Chase & Co. increased their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. BMO Capital Markets raised their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright boosted their price target on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $19.43.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.